文献速递膀胱癌与上尿路尿路上皮癌

铂类难治性晚期尿路上皮癌中免疫检查点抑制剂的比较有效性

Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma.
PubMed 文献 · J Urol · 2020-10-20

本研究基于真实世界去标识数据库,纳入609例铂类化疗后进展的转移性尿路上皮癌患者,比较阿替利珠单抗、纳武利尤单抗和帕博利珠单抗的疗效。匹配加权分析未显示各PD-1/L1抑制剂在至三线治疗启动或死亡时间及总生存期方面存在显著差异。

要点

  • 阿替利珠单抗、纳武利尤单抗和帕博利珠单抗至三线治疗或死亡中位时间分别为4.2、5.3和4.5个月。
  • 三药中位总生存期分别为6.4、8.0和8.3个月。
  • 匹配加权分析未发现各PD-1/L1抑制剂间疗效存在显著差异。

核心结论

  • 在铂类难治性局部晚期/不可切除或转移性尿路上皮癌患者中,PD-1/L1抑制剂在至三线治疗启动或死亡时间及总生存期方面的有效性相似。

研究设计与样本

  • 从真实世界去标识数据库提取患者级数据,采用Cox比例风险模型进行匹配加权比较有效性推断。
  • 纳入2016年8月1日至2019年5月1日期间接受一线铂类化疗后进展并启动单药PD-1/L1抑制剂的转移性尿路上皮癌患者,共609例符合条件。

主要发现

  • 阿替利珠单抗、纳武利尤单抗和帕博利珠单抗至三线治疗或死亡的中位时间分别为4.2、5.3和4.5个月。
  • 阿替利珠单抗、纳武利尤单抗和帕博利珠单抗的中位总生存期分别为6.4、8.0和8.3个月。
  • 匹配加权分析未显示各PD-1/L1抑制剂在至三线治疗或死亡时间及总生存期方面存在强证据的差异。

临床怎么用

  • 在铂类难治性转移性尿路上皮癌中,阿替利珠单抗、纳武利尤单抗和帕博利珠单抗的疗效相似,临床选择可综合考虑其他因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Five programmed cell death protein 1 or its ligand (L1) inhibitors are approved for treatment of platinum refractory, locally advanced/unresectable or metastatic urothelial carcinoma. However, their comparative effectiveness is unknown. We compared time to initiation of third therapy or death, and overall survival with different programmed cell death protein 1/L1 inhibitors in patients with platinum refractory metastatic urothelial carcinoma. MATERIALS AND METHODS: Patient-level data were extracted from a real-world de-identified database. Comparative effectiveness was inferred via Cox proportional hazards model, weighted by matching weights. Each patient's propensity for each treatment was modeled via random forest, based on potential drivers of treatment selection. A propensity score for each therapy was used to calculate a matching weight, targeting the same estimand as 1:1 matching of treatment groups with balance among potential confounders. Eligibility criteria included diagnosis of metastatic urothelial carcinoma, receipt of first line treatment with a platinum based chemotherapy, followed by initiation of single agent programmed cell death protein 1/L1 inhibitor after disease progression from August 1, 2016 through May 1, 2019. RESULTS: Overall, 609 patients were eligible for analysis. Median time to initiation of third therapy or death with atezolizumab, nivolumab and pembrolizumab was 4.2, 5.3 and 4.5 months, respectively, and median overall survival was 6.4, 8.0 and 8.3 months, respectively. Matching weighted analyses did not show strong evidence of differences among programmed cell death protein 1/L1 inhibitors in terms of time to initiation of third therapy or death and overall survival. CONCLUSIONS: In this large real-world cohort, effectiveness in terms of time to initiation of third therapy or death and overall survival with programmed cell death protein 1/L1 inhibitors in patients with platinum refractory locally advanced/unresectable or metastatic urothelial carcinoma was similar.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Swami U, Haaland B, Kessel A, et al. Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma. J Urol. 2020. PMID: 33080152. doi:10.1097/JU.0000000000001412

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。